NextCell Pharma AB

Research NextCell Pharma AB (NXTCL) on Bullrun: market cap SEK 110.39M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerNXTCL
• ExchangeST
• CountrySweden
• SectorHealthcare
• IndustryBiotechnology
• CurrencySEK
• Market capSEK 110.39M
• Financial periodQ4 2025
• RevenueSEK 1.77M
• Net income-SEK 13.79M
• Free cash flow-SEK 10.16M
• Gross margin-9.0%

Valuation Snapshot

latest market cap is SEK 110.39M.

About NextCell Pharma AB

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden.

Frequently asked questions

What is NextCell Pharma AB's market cap?

NextCell Pharma AB's market capitalization is SEK 110.39M.

What does NextCell Pharma AB do?

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden.